Elevated blood lactate in COPD exacerbations associates with adverse clinical outcomes and signals excessive treatment with β2 -agonists
© 2023 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology..
BACKGROUND AND OBJECTIVE: Raised blood lactate secondary to high dose β2 -agonist treatment has been reported in asthma exacerbations but has not been investigated during acute exacerbations of COPD (AECOPD). We explored associations of blood lactate measurements with disease outcomes and β2 -agonist treatments during AECOPD.
METHODS: Retrospective (n = 199) and prospective studies (n = 142) of patients hospitalized with AECOPD were conducted. The retrospective cohort was identified via medical records and the prospective cohort was recruited during hospitalization for AECOPD. Baseline demographics, comorbidities, β2 -agonist treatment, biochemical measurements and clinical outcomes were compared between patients with normal (≤2.0 mmol/L) versus elevated lactate (>2.0 mmol/L). Regression analyses examined associations of lactate measurements with β2 -agonist dosages.
RESULTS: Demographic data and comorbidities were similar between high versus normal lactate groups in both cohorts. The populations were elderly (mean >70 years), predominantly male (>60%) with reduced FEV1 (%) 48.2 ± 19 (prospective cohort). Lactate was elevated in approximately 50% of patients during AECOPD and not related to evidence of sepsis. In the prospective cohort, patients with high lactate had more tachypnoea, tachycardia, acidosis and hyperglycaemia (p < 0.05) and received more non-invasive ventilation (37% vs. 9.7%, p < 0.001, prospective cohort). There was a trend to longer hospitalization (6 vs. 5 days, p = 0.06, prospective cohort). Higher cumulative β2 -agonist dosages were linked to elevated lactate levels (OR 1.04, p = 0.01).
CONCLUSION: Elevated lactate during AECOPD was common, unrelated to sepsis and correlated with high cumulative doses of β2 -agonists. Raised lactate may indicate excessive β2 -agonist treatment and should now be investigated as a possible biomarker.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Respirology (Carlton, Vic.) - 28(2023), 9 vom: 01. Sept., Seite 860-868 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
MacDonald, Martin I [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
β2-agonist |
|---|
| Anmerkungen: |
Date Completed 21.08.2023 Date Revised 21.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/resp.14534 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359013007 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359013007 | ||
| 003 | DE-627 | ||
| 005 | 20231226075947.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/resp.14534 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM359013007 | ||
| 035 | |a (NLM)37400102 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a MacDonald, Martin I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Elevated blood lactate in COPD exacerbations associates with adverse clinical outcomes and signals excessive treatment with β2 -agonists |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.08.2023 | ||
| 500 | |a Date Revised 21.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology. | ||
| 520 | |a BACKGROUND AND OBJECTIVE: Raised blood lactate secondary to high dose β2 -agonist treatment has been reported in asthma exacerbations but has not been investigated during acute exacerbations of COPD (AECOPD). We explored associations of blood lactate measurements with disease outcomes and β2 -agonist treatments during AECOPD | ||
| 520 | |a METHODS: Retrospective (n = 199) and prospective studies (n = 142) of patients hospitalized with AECOPD were conducted. The retrospective cohort was identified via medical records and the prospective cohort was recruited during hospitalization for AECOPD. Baseline demographics, comorbidities, β2 -agonist treatment, biochemical measurements and clinical outcomes were compared between patients with normal (≤2.0 mmol/L) versus elevated lactate (>2.0 mmol/L). Regression analyses examined associations of lactate measurements with β2 -agonist dosages | ||
| 520 | |a RESULTS: Demographic data and comorbidities were similar between high versus normal lactate groups in both cohorts. The populations were elderly (mean >70 years), predominantly male (>60%) with reduced FEV1 (%) 48.2 ± 19 (prospective cohort). Lactate was elevated in approximately 50% of patients during AECOPD and not related to evidence of sepsis. In the prospective cohort, patients with high lactate had more tachypnoea, tachycardia, acidosis and hyperglycaemia (p < 0.05) and received more non-invasive ventilation (37% vs. 9.7%, p < 0.001, prospective cohort). There was a trend to longer hospitalization (6 vs. 5 days, p = 0.06, prospective cohort). Higher cumulative β2 -agonist dosages were linked to elevated lactate levels (OR 1.04, p = 0.01) | ||
| 520 | |a CONCLUSION: Elevated lactate during AECOPD was common, unrelated to sepsis and correlated with high cumulative doses of β2 -agonists. Raised lactate may indicate excessive β2 -agonist treatment and should now be investigated as a possible biomarker | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COPD | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a blood lactate | |
| 650 | 4 | |a chronic obstructive pulmonary disease | |
| 650 | 4 | |a exacerbations | |
| 650 | 4 | |a non-invasive ventilation | |
| 650 | 4 | |a salbutamol | |
| 650 | 4 | |a β2-agonist | |
| 650 | 7 | |a Adrenergic beta-2 Receptor Agonists |2 NLM | |
| 650 | 7 | |a Lactates |2 NLM | |
| 700 | 1 | |a Polkinghorne, Kevan R |e verfasserin |4 aut | |
| 700 | 1 | |a MacDonald, Chris J |e verfasserin |4 aut | |
| 700 | 1 | |a Leong, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Hamza, Kais |e verfasserin |4 aut | |
| 700 | 1 | |a Kathriachchige, Gayan |e verfasserin |4 aut | |
| 700 | 1 | |a Osadnik, Christian Robert |e verfasserin |4 aut | |
| 700 | 1 | |a King, Paul T |e verfasserin |4 aut | |
| 700 | 1 | |a Bardin, Philip G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respirology (Carlton, Vic.) |d 1998 |g 28(2023), 9 vom: 01. Sept., Seite 860-868 |w (DE-627)NLM093444214 |x 1440-1843 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:9 |g day:01 |g month:09 |g pages:860-868 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/resp.14534 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 9 |b 01 |c 09 |h 860-868 | ||